| Autor: |
Noale M; National Research Council, Neuroscience Institute, Aging Branch, 35128 Padua, Italy., Bruni A; Radiotherapy Unit, University Hospital of Modena, 41124 Modena, Italy., Triggiani L; Radiation Oncology Department, University and Spedali Civili Hospital, 25123 Brescia, Italy., Buglione M; Radiation Oncology Department, University and Spedali Civili Hospital, 25123 Brescia, Italy., Bertoni F; Prostate Group of the Italian Association for Radiation Oncology (AIRO), 20124 Milan, Italy., Frassinelli L; Radiotherapy Unit, University Hospital of Modena, 41124 Modena, Italy., Montironi R; Section of Pathological Anatomy, Polytechnic University of the Marche Region, 60126 Ancona, Italy., Corvò R; Department of Radiation Oncology, Ospedale Policlinico San Martino and University of Genoa, 16132 Genoa, Italy., Zagonel V; Medical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy., Porreca A; Urological Oncology, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy., Bassi P; Department of Urology, Catholic University of Rome, Policlinico Gemelli, 00168 Rome, Italy., Gacci M; Department of Urologic Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, 50134 Florence, Italy., Conti GN; Urology Unit, Azienda Socio-Sanitaria Territoriale Lariana, Sant'Anna Hospital, 22042 Como, Italy., Maggi S; National Research Council, Neuroscience Institute, Aging Branch, 35128 Padua, Italy., Magrini S; Radiation Oncology Department, University and Spedali Civili Hospital, 25123 Brescia, Italy., The Pros-It Cnr Study Group |
| Abstrakt: |
Radiotherapy (RT) represents an important therapeutic option for the treatment of localized prostate cancer. The aim of the current study is to examine trajectories in patients' reported quality of life (QoL) aspects related to bowel function and bother, considering data from the PROState cancer monitoring in ITaly from the National Research Council (Pros-IT CNR) study, analyzed with growth mixture models. Data for patients who underwent RT, either associated or not associated with androgen deprivation therapy, were considered. QoL outcomes were assessed over a 2-year period from the diagnosis, using the Italian version of the University of California Los Angeles-Prostate Cancer Index (Italian-UCLA-PCI). Three trajectories were identified for the bowel function; having three or more comorbidities and the use of 3D-CRT technique for RT were associated with the worst trajectory (OR = 3.80, 95% CI 2.04-7.08; OR = 2.17, 95% CI 1.22-3.87, respectively). Two trajectories were identified for the bowel bother scores; diabetes and the non-Image guided RT method were associated with being in the worst bowel bother trajectory group (OR = 1.69, 95% CI 1.06-2.67; OR = 2.57, 95% CI 1.70-3.86, respectively). The findings from this study suggest that the absence of comorbidities and the use of intensity modulated RT techniques with image guidance are related with a better tolerance to RT in terms of bowel side effects. |
